Skip to main content
logo
Agilent Technologies, Inc. (A)
NYSE: A · Real-Time Price · USD
116.87
+2.99 (2.63%)
Apr 8, 2026, 11:32 AM EDT - Market open

Revenue Breakdown

Millions USD. Fiscal year is Nov - Oct.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Jan '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21 Oct '20 Oct '19 Oct '18 Oct '17 Oct '16 Oct '15 Oct '14 Oct '13 Oct '12
Life Sciences & Diagnostics Markets Revenue
2.76B2.73B2.47B
Life Sciences & Diagnostics Markets Revenue Growth
1.17%10.54%-
Agilent CrossLab Revenue (Post-FY2024 Reporting)
2.97B2.91B2.75B
Agilent CrossLab Revenue (Post-FY2024 Reporting) Growth
2.13%5.86%-
Applied Markets Revenue
1.34B1.31B1.30B
Applied Markets Revenue Growth
1.75%1.31%-
Revenue (Total)
7.07B6.95B6.51B
Revenue (Total) Growth
1.68%6.73%-4.73%

Revenue Breakdown 2

Millions USD. Fiscal year is Nov - Oct.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Jan '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21 Oct '20 Oct '19 Oct '18 Oct '17 Oct '16 Oct '15 Oct '14 Oct '13 Oct '12
Life Sciences & Applied Markets Revenue
--3.22B
Life Sciences & Applied Markets Revenue Growth
---8.40%
Diagnostics & Genomics Revenue
--1.65B
Diagnostics & Genomics Revenue Growth
---5.93%
Agilent CrossLab Revenue (Pre-FY2025 Reporting)
--1.64B
Agilent CrossLab Revenue (Pre-FY2025 Reporting) Growth
--4.85%
Revenue (Total)
7.07B6.95B6.51B
Revenue (Total) Growth
1.68%6.73%-4.73%

EBIT

Millions USD. Fiscal year is Nov - Oct.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Jan '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21 Oct '20 Oct '19 Oct '18 Oct '17 Oct '16 Oct '15 Oct '14 Oct '13 Oct '12
Life Sciences & Diagnostics Markets Income from Operations
528.00M536.00M484.00M
Life Sciences & Diagnostics Markets Income from Operations Growth
-1.49%10.74%-
Agilent CrossLab Income from Operations (Post-FY2024 Reporting)
965.00M946.00M925.00M
Agilent CrossLab Income from Operations (Post-FY2024 Reporting) Growth
2.01%2.27%-
Applied Markets Income from Operations
310.00M301.00M312.00M
Applied Markets Income from Operations Growth
2.99%-3.53%-
Operating Income (Other)
-347.00M-304.00M-233.00M
Operating Income (Total)
1.46B1.48B1.49B
Operating Income (Total) Growth
-1.55%-0.60%10.22%

EBIT 2

Millions USD. Fiscal year is Nov - Oct.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Jan '26 Oct '25 Oct '24 Oct '23 Oct '22 Oct '21 Oct '20 Oct '19 Oct '18 Oct '17 Oct '16 Oct '15 Oct '14 Oct '13 Oct '12
Life Sciences & Applied Markets Income from Operations
--877.00M
Life Sciences & Applied Markets Income from Operations Growth
---16.40%
Diagnostics & Genomics Income from Operations
--320.00M
Diagnostics & Genomics Income from Operations Growth
---11.85%
Agilent CrossLab Income from Operations (Pre-FY2025 Reporting)
--524.00M
Agilent CrossLab Income from Operations (Pre-FY2025 Reporting) Growth
--13.18%
Operating Income (Total)
1.46B1.48B1.49B
Operating Income (Total) Growth
-1.55%-0.60%10.22%
Updated Jan 31, 2026. Data Source: Fiscal.ai.